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A B S T R A C T
Left atrial appendage (LAA) occlusion is a potential alternative to warfarin in pa-
tients with atrial fibrillation who have contraindications to anticoagulation. Current-
ly, there are two devices specifically designed for percutaneous LAA occlusion: the 
Percutaneous LAA Transcatheter Occlusion (PLAATO System, ev3 Inc., Plymouth, 
Minnesota) and the WATCHMAN LAA system (Atritech Inc., Plymouth, Minne-
sota). Despite early interesting and promising data from the PLAATO device, this 
device was withdrawn by the manufacturer in 2006. Early data on the WATCHMAN 
system were reported in 2007, and this device is the focus of the recently published 
PROTECT-AF (WATCHMAN Left Atrial Appendage System for Embolic Protec-
tion in Patients with Atrial Fibrillation) study. According to the results of the study, 
the efficacy of percutaneous closure of the LAA with this device was non-inferior to 
that of warfarin therapy, suggesting that closure of the LAA might provide an alterna-
tive strategy to chronic warfarin therapy for stroke prophylaxis in patients with non-
valvular atrial fibrillation.
I N T R O D U C T I O N
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, af-
fecting an estimated 6 million Americans.1 Among patients with AF, there is an ap-
proximate 5% annual stroke risk, a 5-fold increase over an age-matched population 
in sinus rhythm.2 The efficacy of oral anticoagulation (OAC) in lowering the risk of 
stroke and death in patients with nonrheumatic AF, has been clearly demonstrated 
by multiple randomized, controlled trials.3-6 Warfarin confers a 68% relative risk re-
duction compared with non–warfarin-treated control subjects, reducing absolute risk 
from 4.8% to 1.8% per year.7 Aspirin (ASA) confers lesser benefit, with a relative risk 
reduction as high as 44% compared with control subjects, but this may be substantially 
less in individuals at high risk for stroke.4,8 Chronic OAC with warfarin appears to 
have a lot of problems of safety and acceptability for many patients. Patients treated 
with warfarin achieve a therapeutic range only in 50% to 68% of monitored days.9 In 
clinical practice, oral anticoagulants are prescribed to only 15% to 66% of patients 
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with AF who are at high risk for thromboembolic events and 
have no clear contraindication to their use.10
T H E  R O L E  O F  L E F T  A T R I A L  A P P E N D A G E  I N 
T H R O M B O E M B O L I S M  I N  A T R I A L  F I B R I L L A -
T I O N
The risk of stroke is increased in patients with AF, pre-
sumably because stagnant blood flow within the left atrium 
leads to thrombus formation. The most common location of 
thrombi (>90%), proved by echocardiography in patients with 
nonrheumatic AF, is the left atrial appendage (LAA).3,7,11 In 
most patients, the LAA is a discrete anatomic structure,12-14 
and it may be relatively easily excluded from systemic circula-
tion. LAA amputation or oversewing of its orifice is routinely 
done to minimize the risk of future thromboembolism and it 
is often performed in surgery for rheumatic mitral valve dis-
ease, which is often accompanied by AF. Minimally invasive 
transthoracic techniques also have been used to achieve the 
same result with mixed outcomes—suturing the LAA either 
from within or without may occlude the orifice of the LAA 
but persistent flow into and out of the LAA is frequently seen 
when such patients have echocardiograms at follow-up.
P E R C U T A N E O U S  T R A N S C A T H E T E R  O C C L U S I O N 
O F  T H E  L E F T  A T R I A L  A P P E N D A G E
Currently there are two devices specifically designed for 
percutaneous transcatheter LAA occlusion: the Percutaneous 
LAA Transcatheter Occlusion (PLAATO System, ev3 Inc., 
Plymouth, Minnesota) and the WATCHMAN LAA system 
(Atritech Inc., Plymouth, Minnesota).
The PLAATO device is a self-expanding nitinol cage 
ranging from 15 to 32 mm in diameter and is covered with 
a polytetrafluoroethylene membrane to close off flow into 
the LAA. The feasibility and safety of PLAATO was first 
described in a dog model,15 and it has already been tested in 
a phase I clinical trial. The PLAATO System Trial included 
only patients with nonrheumatic AF who were at high risk for 
ischemic stroke and who were not candidates for long-term 
anticoagulation with warfarin. This group of patients had a 
history of stroke or transient ischemic attack or at least one 
(in Europe) or two (in the United States) stroke risk factors 
(age >65 years, hypertension, heart failure, diabetes, coronary 
artery disease, and moderate or dense spontaneous echo 
contrast or velocity <20 cm/s in the LAA), with a predicted 
stroke risk based on the patients’ adjusted CHADS score16 
distribution of 6.3% per year. According to the results of the 
trial, transcatheter implantation of the PLAATO device was 
feasible, reasonably safe, and raised the possibility that the 
incidence of stroke after PLAATO implantation was reduced. 
The observed annual stroke rate was 2.2% representing a 65% 
relative stroke risk reduction with the PLAATO procedure. 
Of the 111 enrolled patients, with an average follow up of 9.8 
months, two experienced a stroke, 173 and 215 days after the 
implant procedure.
A later report in a larger group of PLAATO patients, with 
a mean follow up of 14.7 months,17 indicated that the actual 
stroke rate was reduced to 3.2% (a relative risk reduction of 
about 50%), while regarding the long-term risk of thrombus 
formation with the PLAATO procedure, thrombus formation 
was present in 2 patients after 48 months of follow up.18 One 
thrombus was formed on the external surface of the device 
and the other thrombus was formed in the interatrial septum. 
For the same follow up period, peak flow velocities of the 
pulmonary veins were not significantly higher after position-
ing of the device, indicating that there is no development of 
pulmonary venous obstruction. Despite early interesting and 
promising data from the PLAATO device, this device was 
withdrawn by the manufacturer in 2006.19
The WATCHMAN LAA system is another percutaneous 
device for LAA occlusion that is placed in the LAA through a 
transseptal approach. The implant has a 160-μm polyethylene 
membrane on the proximal face of a nitinol frame structure 
covered with a permeable polyester fabric that allows blood 
inflow but excludes passage of thrombi out of the LAA, de-
veloping a mechanical barrier to avoid embolization from the 
LAA.20 Sick et al in 2007 published a study that demonstrated 
that implantation of the WATCHMAN device is a gener-
ally safe and feasible method for percutaneously sealing the 
LAA.21 In a population of 66 patients with average CHADS 
score of 1.8, indicating a moderate level of risk for stroke, and 
a follow up period of 45 days, 99% of the devices satisfied the 
primary efficacy end point with complete closure of the LAA. 
The expected annual risk of stroke for the studied group based 
on the CHADS score was calculated to be 1.9 per year. At a 
mean follow-up of 24 ±11 months, no strokes were reported, 
despite discontinuation of anticoagulation in >90% of the 
patients. Two patients experienced device embolization; both 
were successfully retrieved percutaneously and no further em-
bolizations occurred, while five pericardial effusions and one 
major air embolism occurred without long-term sequelae.22
A prospective, randomized study, designed to prove the 
noninferiority of the WATCHMAN device to warfarin in 
patients with AF was published recently.23,24 In the WATCH-
MAN Left Atrial Appendage System for Embolic PROTEC-
Tion in Patients With Atrial Fibrillation (PROTECT AF) 
study, a multicenter, non-inferiority trial, the efficacy and 
safety of implantation of the percutaneous LAA closure de-
vice was compared with that of long-term warfarin therapy. 
More than 700 patients fulfilled the inclusion criteria of 
having non-valvular atrial fibrillation, being suitable for an-
ticoagulation, and having a CHADS2 risk score of 1 or more. 
Most of the patients who had the device implanted (349 of 
408) stopped warfarin at 45 days (as predefined) once there 
was transoesophageal echocardiographic confirmation of 
LAA closure, and remained on aspirin and clopidogrel for 
6 months after randomization, followed by long-term aspirin 
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monotherapy. The probability of non-inferiority of the device 
was greater than 99.9% with regard to the primary efficacy 
outcome (occurrence of all types of stroke, cardiovascular or 
unexplained death, or systemic emboli within up to 3 years), 
and patients who received the device had fewer hemorrhagic 
strokes than the controls. However, the primary safety end-
point (which combined major bleeding, serious pericardial 
effusion, and device embolization) was significantly greater 
in the device group than in the control group.23
The potential concerns with LAA exclusion devices in-
clude the elimination of the hemodynamics and endocrine 
properties of the LAA.25 Data from animals and humans 
indicate that the LAA elimination may aggravate heart failure, 
and because of the anatomical proximity, LAA occlusion may 
impede flow in the left coronary artery circumflex branch.13 
Although rare, device migration, dislodgement or emboliza-
tion, and cardiac perforation may be potential problems; and 
repeat procedures may be required. Furthermore iatrogenic 
small atrial septal defects can be created. They usually disap-
pear within 6 months of the procedure. Persistence of atrial 
septal defects up to 6 months was observed in three of 48 
(6%) patients treated with the PLAATO device18 that were 
evaluated with transesophageal echo (TEE), the role of which 
during the implantation process as well as in the follow up of 
the patients is of great importance.
C O N C L U S I O N
The left atrial appendage occlusion is a potential alterna-
tive to warfarin in patients with atrial fibrillation who have 
contraindications to anticoagulation. As the PROTECT-AF 
study is the first randomized trial of its kind, the precise 
role of the WATCHMAN device in the current approach to 
stroke prevention in patients with atrial fibrillation is perhaps 
premature. However, we must admit that these results are 
very encouraging at least for the usage of the device as an 
alternative option for patients who are unable to take long-
term warfarin.
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